Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Tax Provisions (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Tax Provisions for 12 consecutive years, with -$6.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Tax Provisions fell 345.8% to -$6.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $17.9 million, a 165.62% increase, with the full-year FY2024 number at $11.8 million, up 334.45% from a year prior.
  • Tax Provisions was -$6.5 million for Q3 2025 at Theravance Biopharma, down from $18.4 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $18.4 million in Q2 2025 to a low of -$6.5 million in Q3 2025.
  • A 5-year average of $1.6 million and a median of $227000.0 in 2021 define the central range for Tax Provisions.
  • Peak YoY movement for Tax Provisions: plummeted 664.1% in 2021, then skyrocketed 29260.0% in 2023.
  • Theravance Biopharma's Tax Provisions stood at -$7000.0 in 2021, then skyrocketed by 57.14% to -$3000.0 in 2022, then skyrocketed by 45666.67% to $1.4 million in 2023, then skyrocketed by 381.93% to $6.6 million in 2024, then plummeted by 198.72% to -$6.5 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Tax Provisions are -$6.5 million (Q3 2025), $18.4 million (Q2 2025), and -$600000.0 (Q1 2025).